loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Pixantrone

    Client Email Product
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-09-09

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    Virtual Booth

    Contact Supplier

    Veranova: A CDMO that manages complexity with confidence.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-09-09

    Virtual Booth

    Contact Supplier

    Menu

    Pixantrone

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Servier acquires Pixuvri from CTI BioPharma
    Servier acquires Pixuvri from CTI BioPharma

    04 Oct 2019

    // A.Smith PHARMA TIMES

    http://www.pharmatimes.com/news/servier_acquires_pixuvri_from_cti_biopharma_1311745

    A.Smith PHARMA TIMES
    04 Oct 2019
    Share Share
    Servier acquires non-Hodgkin B-cell lymphoma treatment PIXUVRI® (pixantrone)
    Servier acquires non-Hodgkin B-cell lymphoma treatment PIXUVRI® (pixantrone)

    02 Oct 2019

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20190930005875/en

    BUSINESSWIRE
    02 Oct 2019
    Share Share
    Servier acquire non-Hodgkin B-cell lymphoma treatment PIXUVRI® from CTI BioPharm
    Servier acquire non-Hodgkin B-cell lymphoma treatment PIXUVRI® from CTI BioPharm

    30 Sep 2019

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20190930005875/en/Servier-acquires-non-Hodgkin-B-cell-lymphoma-treatment-PIXUVRI%C2%AE

    BUSINESSWIRE
    30 Sep 2019
    Share Share
    PIXUVRI® (pixantrone) Receives +ve CHMP Opinion to Convert Conditional Approval
    PIXUVRI® (pixantrone) Receives +ve CHMP Opinion to Convert Conditional Approval

    09 Apr 2019

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20190409005183/en/PIXUVRI%C2%AE-pixantrone-Receives-Positive-CHMP-Opinion-Convert/?feedref=JjAwJuNHiystnCoBq_hl-bQQCakZDujohEJegUyaJwquReQ0P23MrIoWkrUSV24ZevRMp3sIgu8q3wq1OF24lT93qbEzrwa15HGbLqMObxbNWfZlBntHS6jpH5ROLXsTFMkl05DM8ABqeyBleEmzJA==

    BUSINESSWIRE
    09 Apr 2019
    Share Share
    CTI, Servier’s Pixuvri fails in post-marketing trial
    CTI, Servier’s Pixuvri fails in post-marketing trial

    10 Jul 2018

    // Selina McKee PHARMA TIMES

    http://www.pharmatimes.com/news/cti,_serviers_pixuvri_fails_in_post-marketing_trial_1243743

    Selina McKee PHARMA TIMES
    10 Jul 2018
    Share Share
    CTI Biopharma Says Phase III Trial Evaluating Pixuvri With Rituximab In Comparison To Gemcitabine Combined With Rituximab Did Not Meet Its Primary Endpoint
    CTI Biopharma Says Phase III Trial Evaluating Pixuvri With Rituximab In Comparison To Gemcitabine Combined With Rituximab Did Not Meet Its Primary Endpoint

    10 Jul 2018

    // REUTERS

    https://www.reuters.com/finance/stocks/CTIC.OQ/key-developments/article/3862357

    REUTERS
    10 Jul 2018
    Share Share